Company Analysis
Sign in

Indaptus Therapeutics, Inc. (INDP)

Nasdaq: INDP · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.3
◀ Past 4.0● Present 2.0▶ Future 6.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$20.8M-38.8%
Earnings per share$-21.58+52.0%
Operating cash flow-$14.8M-20.3%
Cash$8.5M+47.0%
Debtn/a
Shareholders’ equity$3.2M-20.1%
Shares, diluted966,124+189.1%
Return on equity-661.5%
The recordfrom its filings
Filings in 202660
Newest filingOct 22 · SCHEDULE 13D/A
Annual reportMar 17, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted1
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$15.4MCash from operations -$14.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 20, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 10, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 4, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton INDP · research, not advice